ArticleFrontiers in pharmacology2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China.

Wenwang Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.